Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MTNB Stock Summary
Top 10 Correlated ETFs
MTNB
In the News
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Penny Stocks To Buy Now? 3 to Watch With Big News
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.
Matinas BioPharma to Present at Two Investment Conferences in October 2023
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time. The conference is being held at the New York Hilton Midtown.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
7 Small-Cap Biotech Stocks with Massive Potential
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
MTNB Financial details
MTNB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
Net income per share | -0.14 | -0.11 | -0.1 | -0.1 | -0.06 | |
Operating cash flow per share | -0.11 | -0.1 | -0.09 | -0.07 | -0.09 | |
Free cash flow per share | -0.11 | -0.1 | -0.09 | -0.07 | -0.09 | |
Cash per share | 0.13 | 0.19 | 0.3 | 0.24 | 0.13 | |
Book value per share | 0.16 | 0.23 | 0.32 | 0.25 | 0.17 | |
Tangible book value per share | 0.12 | 0.2 | 0.3 | 0.23 | 0.15 | |
Share holders equity per share | 0.16 | 0.23 | 0.32 | 0.25 | 0.17 | |
Interest debt per share | 0 | 0.03 | 0.02 | 0.02 | 0 | |
Market cap | 58.37M | 329.59M | 267.78M | 212.28M | 108.41M | |
Enterprise value | 46.32M | 311.65M | 259.09M | 195.95M | 105.7M | |
P/E ratio | -4.14 | -21.15 | -13 | -10.03 | -8.33 | |
Price to sales ratio | 487.44 | 3.66K | 1.69K | 6.37K | 34 | |
POCF ratio | -5.66 | -23.39 | -15.42 | -13.94 | -5.66 | |
PFCF ratio | -5.38 | -22.73 | -15.41 | -13.71 | -5.41 | |
P/B Ratio | 3.62 | 9.97 | 4.2 | 4.04 | 2.96 | |
PTB ratio | 3.62 | 9.97 | 4.2 | 4.04 | 2.96 | |
EV to sales | 386.77 | 3.46K | 1.64K | 5.88K | 33.16 | |
Enterprise value over EBITDA | -3.21 | -15.64 | -10.25 | -7.52 | -3.76 | |
EV to operating cash flow | -4.49 | -22.12 | -14.92 | -12.87 | -5.52 | |
EV to free cash flow | -4.27 | -21.5 | -14.91 | -12.66 | -5.27 | |
Earnings yield | -0.24 | -0.05 | -0.08 | -0.1 | -0.12 | |
Free cash flow yield | -0.19 | -0.04 | -0.06 | -0.07 | -0.18 | |
Debt to equity | 0.02 | 0.13 | 0.06 | 0.09 | 0.11 | |
Debt to assets | 0.02 | 0.11 | 0.05 | 0.08 | 0.09 | |
Net debt to EBITDA | 0.84 | 0.9 | 0.34 | 0.63 | 0.1 | |
Current ratio | 4.61 | 9.66 | 17.25 | 11.73 | 8.06 | |
Interest coverage | 0 | 0 | 0 | 0 | 6.84 | |
Income quality | 0.73 | 0.81 | 0.77 | 0.65 | 0.91 | |
Dividend Yield | 10.06 | 6.78 | 2.55 | 3.97 | 0 | |
Payout ratio | -41.69 | -143.37 | -33.15 | -39.84 | 0 | |
Sales general and administrative to revenue | 66.63 | 86.4 | 63.2 | 305.55 | 3.48 | |
Research and developement to revenue | 56.68 | 124.83 | 90.69 | 437.5 | 5.23 | |
Intangibles to total assets | 0.22 | 0.11 | 0.06 | 0.07 | 0.1 | |
Capex to operating cash flow | 0.05 | 0.03 | 0 | 0.02 | 0.05 | |
Capex to revenue | -4.48 | -4.51 | -0.04 | -7.81 | -0.28 | |
Capex to depreciation | -2.45 | -0.52 | -0.01 | -0.33 | -0.99 | |
Stock based compensation to revenue | 32.01 | 33.17 | 28.83 | 128.77 | 1.64 | |
Graham number | 0.73 | 0.74 | 0.87 | 0.75 | 0.48 | |
ROIC | -0.85 | -0.41 | -0.31 | -0.36 | -0.34 | |
Return on tangible assets | -0.9 | -0.43 | -0.31 | -0.37 | -0.32 | |
Graham Net | 0.09 | 0.14 | 0.26 | 0.19 | 0.09 | |
Working capital | 10.25M | 26.83M | 57.99M | 46.64M | 30.25M | |
Tangible asset value | 11.79M | 28.7M | 59.38M | 48.14M | 32.28M | |
Net current asset value | 9.28M | 22.73M | 54.32M | 42.16M | 26.35M | |
Invested capital | 0.02 | 0.13 | 0.06 | 0.09 | 0.11 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 439.26K | 487.33K | 514.47K | 644.11K | 778.14K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 22.06 | 8.9 | 438.22 | 13.53 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 16.55 | 41.03 | 0.83 | 26.99 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.87 | -0.47 | -0.32 | -0.4 | -0.36 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.01 | 0 | 0 | |
Net income per share | -0.03 | 0 | -0.03 | -0.03 | -0.03 | |
Operating cash flow per share | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | |
Free cash flow per share | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | |
Cash per share | 0.15 | 0.13 | 0.11 | 0.1 | 0.08 | |
Book value per share | 0.18 | 0.17 | 0.15 | 0.13 | 0.11 | |
Tangible book value per share | 0.16 | 0.15 | 0.13 | 0.11 | 0.09 | |
Share holders equity per share | 0.18 | 0.17 | 0.15 | 0.13 | 0.11 | |
Interest debt per share | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
Market cap | 137.93M | 108.41M | 102.11M | 78.22M | 28.24M | |
Enterprise value | 130.98M | 105.7M | 100.36M | 72.33M | 25.55M | |
P/E ratio | -6.31 | -832.23 | -4.69 | -3.23 | -1.17 | |
Price to sales ratio | 129.81 | 101.98 | 93.17 | 0 | 0 | |
POCF ratio | -27.76 | -25.21 | -24.99 | -35.67 | -6.39 | |
PFCF ratio | -26.43 | -24.97 | -24.99 | -32.66 | -6.37 | |
P/B Ratio | 3.57 | 2.96 | 3.13 | 2.81 | 1.22 | |
PTB ratio | 3.57 | 2.96 | 3.13 | 2.81 | 1.22 | |
EV to sales | 123.28 | 99.44 | 91.57 | 0 | 0 | |
Enterprise value over EBITDA | -25.04 | -15.08 | -18.74 | -12.21 | -4.16 | |
EV to operating cash flow | -26.36 | -24.58 | -24.56 | -32.98 | -5.78 | |
EV to free cash flow | -25.1 | -24.35 | -24.56 | -30.2 | -5.76 | |
Earnings yield | -0.04 | 0 | -0.05 | -0.08 | -0.21 | |
Free cash flow yield | -0.04 | -0.04 | -0.04 | -0.03 | -0.16 | |
Debt to equity | 0.11 | 0.11 | 0.12 | 0.14 | 0.16 | |
Debt to assets | 0.09 | 0.09 | 0.1 | 0.11 | 0.12 | |
Net debt to EBITDA | 1.33 | 0.39 | 0.33 | 0.99 | 0.44 | |
Current ratio | 7.57 | 8.06 | 14.88 | 9.27 | 6.19 | |
Interest coverage | 5.53K | 2.97 | 76.52 | 0 | 0 | |
Income quality | 0.91 | 1.18 | 0.74 | 0.36 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.03 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.65 | 2.52 | 2.47 | 0 | 0 | |
Research and developement to revenue | 3.49 | 3.64 | 3.62 | 0 | 0 | |
Intangibles to total assets | 0.09 | 0.1 | 0.11 | 0.13 | 0.15 | |
Capex to operating cash flow | 0.05 | 0.01 | 0 | 0.09 | 0 | |
Capex to revenue | -0.24 | -0.04 | 0 | 0 | 0 | |
Capex to depreciation | -1.08 | -0.18 | 0 | -0.86 | -0.07 | |
Stock based compensation to revenue | 1.33 | 1.26 | 1.16 | 0 | 0 | |
Graham number | 0.32 | 0.02 | 0.29 | 0.28 | 0.26 | |
ROIC | -0.12 | 0 | -0.14 | -0.17 | -0.19 | |
Return on tangible assets | -0.13 | 0 | -0.16 | -0.2 | -0.24 | |
Graham Net | 0.11 | 0.09 | 0.09 | 0.08 | 0.05 | |
Working capital | 32.2M | 30.25M | 26.31M | 21.41M | 16.76M | |
Tangible asset value | 34.26M | 32.28M | 28.27M | 23.5M | 18.8M | |
Net current asset value | 28.17M | 26.35M | 22.57M | 17.83M | 13.35M | |
Invested capital | 0.11 | 0.11 | 0.12 | 0.14 | 0.16 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 576.93K | 637.36K | 567K | 560K | 719.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 256.1 | 15.93 | 202.79 | 232.31 | 315.76 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.35 | 5.65 | 0.44 | 0.39 | 0.29 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.14 | 0 | -0.17 | -0.22 | -0.26 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MTNB Frequently Asked Questions
What is Matinas BioPharma Holdings, Inc. stock symbol ?
Matinas BioPharma Holdings, Inc. is a US stock , located in Bedminster of Nj and trading under the symbol MTNB
What is Matinas BioPharma Holdings, Inc. stock quote today ?
Matinas BioPharma Holdings, Inc. stock price is $0.271 today.
Is Matinas BioPharma Holdings, Inc. stock public?
Yes, Matinas BioPharma Holdings, Inc. is a publicly traded company.